辉瑞新冠口服药获附条件批准上市

China's drug regulator on Friday granted conditional approval for the imports of Pfizer's Paxlovid COVID-19 pill.

2月11日，国家药监局附条件批准辉瑞公司新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装(即Paxlovid)进口注册。

The pill is a small-molecule oral drug, a co-package of antiviral drugs nirmatrelvir tablets and ritonavir tablets, for adults who are experiencing mild to moderate symptoms and who are at a higher risk of becoming more seriously ill, according to the National Medical Products Administration. It can be given to patients who, for instance, are older in age or have chronic renal diseases, diabetes, cardiovascular diseases, and chronic lung diseases.
国家药监局表示，Paxlovid属小分子口服药，可用于治疗成人伴有进展为重症高风险因素的轻至中度新冠肺炎患者，例如伴有高龄、慢性肾脏疾病、糖尿病、心血管病、慢性肺病等重症高风险因素的患者。